All In MedTech

Device Trial Radar · NCT03326232

Real-time Continuous Glucose Monitoring

Real-time Continuous Glucose Monitoring for the Treatment of Gestational Diabetes: a Randomized Trial

Last checked: Nov 20, 2026Latest source record: Nov 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 13, 2017

Primary completion

Jul 2018

Study completion Jul 2018

Sponsor

Lead sponsor
Eastern Virginia Medical SchoolAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic
First posted
Oct 31, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gestational diabetes (GDM) is a condition of carbohydrate intolerance with onset or first recognition in pregnancy. The prevalence of GDM is as high as 25% in some populations and continues to rise with the increase in obesity and type-2 diabetes. GDM places the pregnancy at great risk to both the mother and the neonate. Recent studies have proven that interventions including dietary and medications lower the risk to the pregnancy. Both the American College of Obstetrics and Gynecology (ACOG) and the American Diabetes Association (ADA) recommend dietary interventions with daily glucose monitoring as the initial treatment of choice. Meanwhile, outside of pregnancy, promising new technologies such as continuous glucose monitors (CGM) are revolutionizing diabetic care. The investigators seek to determine if the constant feedback of a real-time CGM system would improve glycemic control compared to traditional management in GDM

Conditions

  • Gestational Diabetes

Interventions

  • Continuous glucose monitoringDevice

    The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean blood glucose (mg/dL)Time frame: week 1 vs. week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eastern Virginia Medical School

    Norfolk, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.